| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
Omaciclovir targets viral DNA polymerase, specifically inhibiting the replication of herpesviruses. It is phosphorylated by viral thymidine kinase to its monophosphate form and is further modified to a triphosphate, which is an inhibitor of VZV DNA polymerase. This selective activation in virus-infected cells contributes to its antiviral specificity and reduced toxicity to uninfected host cells.
|
|---|---|
| ln Vitro |
Omaciclovir is a nucleoside analog that inhibits the varicella zoster virus (VZV), human herpesvirus 6, Epstein-Barr virus, and herpes simplex virus types 1 and 2. Omaciclovir is also effective against simian varicella virus-infected monkeys [1]. With EC50 values of 0.72 ± 0.1, 0.62 ± 0.2, 0.015 ± 0.004, 0.048 ± 0.023, 0.047 ± 0.004, 0.035 ± 0.022, and 0.016 ± 0.003 μM V for MRC-5 VZ -32, MeWo Molly, MeWo Emily, MeWo VZ11, and MeWo VZ30[1], respectively, omeaciclovir demonstrates antiviral activity against various human herpesviruses.
In vitro, Omaciclovir demonstrates potent antiviral activity against a broad range of herpesviruses, including VZV, HSV-1, HSV-2, Epstein-Barr virus, and human herpesvirus 6. As a nucleoside analog, it inhibits viral DNA polymerase by acting as a chain terminator during DNA replication. Its in vitro activity is typically assessed using plaque reduction assays or viral yield reduction assays in infected cell cultures. |
| ln Vivo |
In vivo activity of Omaciclovir has been demonstrated in animal models of herpesvirus infection, where it shows efficacy in reducing viral replication and disease symptoms. As a prodrug of penciclovir with higher oral bioavailability, it provides improved systemic exposure compared to penciclovir. In vivo efficacy is assessed by measuring reductions in viral titers, lesion severity, and mortality in infected animals.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (cell-free) assay for Omaciclovir involves measuring its inhibitory activity against viral DNA polymerase in cell-free systems. These assays use purified viral DNA polymerase and measure the incorporation of nucleotides into DNA in the presence of the compound. The active triphosphate form of Omaciclovir competes with natural nucleotides for binding to the polymerase active site, resulting in chain termination. Inhibitory potency (IC50) is determined by assessing the reduction in polymerase activity.
|
| Cell Assay |
In vitro cellular assays for Omaciclovir are performed using cell lines infected with herpesviruses, such as VZV, HSV-1, or HSV-2. These assays measure the compound's ability to inhibit viral replication by assessing viral DNA synthesis, plaque formation, or viral protein expression. The selectivity index is determined by comparing the antiviral activity to cytotoxicity in uninfected cells. These assays demonstrate the compound's potent and selective antiviral activity.
|
| Animal Protocol |
In vivo animal studies for Omaciclovir are conducted in rodent models of herpesvirus infection, such as HSV-1 or HSV-2 cutaneous or genital infection models. These studies typically involve oral or parenteral administration of the compound, followed by assessment of viral replication, lesion development, and survival. The prodrug formulation provides improved oral bioavailability, resulting in enhanced efficacy compared to penciclovir. Pharmacokinetic-pharmacodynamic relationships are also evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Omaciclovir are characterized by high oral bioavailability as a prodrug of penciclovir. Following oral administration, it is rapidly absorbed and converted to penciclovir, which is the active antiviral agent. The prodrug design improves the systemic exposure of penciclovir, allowing for less frequent dosing. Penciclovir is primarily excreted renally as unchanged drug, and its half-life supports twice-daily dosing for herpes zoster indications.
|
| Toxicity/Toxicokinetics |
Toxicology studies of Omaciclovir have been conducted to support its clinical use for herpesvirus infections. As a nucleoside analog, it has a favorable safety profile with selectivity for virus-infected cells due to its activation by viral thymidine kinase. Preclinical toxicology studies include acute and repeat-dose toxicity assessments, genotoxicity evaluations, and reproductive toxicity studies. The compound is generally well-tolerated at therapeutic doses.
|
| References | |
| Additional Infomation |
Omasillovir is an acyclic guanosine analogue active against varicella-zoster virus (VZV) and other members of the herpesvirus family. Omasillovir can be selectively phosphorylated to a monophosphate form by viral thymidine kinase and further modified to a triphosphate, which is an inhibitor of VZV DNA polymerase.
Omaciclovir, also known as ABT-091 and H2G, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles) and is marketed as Famvir by Novartis. As a prodrug of penciclovir, it offers improved oral bioavailability and convenient dosing. Clinical studies have demonstrated its efficacy in reducing the duration and severity of herpes zoster and herpes simplex infections. |
| Molecular Formula |
C10H15N5O3
|
|---|---|
| Molecular Weight |
253.2578
|
| Exact Mass |
253.117
|
| CAS # |
124265-89-0
|
| PubChem CID |
135433609
|
| Appearance |
White to off-white solid powder
|
| Density |
1.68g/cm3
|
| Boiling Point |
637.8ºC at 760 mmHg
|
| Flash Point |
339.5ºC
|
| Vapour Pressure |
3.85E-17mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
18
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=NC2=C(N1C[C@@H](CCO)CO)N=C(NC2=O)N
|
| InChi Key |
SCBFBAWJWLXVHS-ZCFIWIBFSA-N
|
| InChi Code |
InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)3-6(4-17)1-2-16/h5-6,16-17H,1-4H2,(H3,11,13,14,18)/t6-/m1/s1
|
| Chemical Name |
2-amino-9-[(2R)-4-hydroxy-2-(hydroxymethyl)butyl]-1H-purin-6-one
|
| Synonyms |
H2G A-182091H 2G A182091(-)-2HM-HBG 2HMHBGABT 091 ABT091 ABT-091
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~230 mg/mL (~908.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5.75 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 57.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5.75 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 57.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5.75 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9485 mL | 19.7426 mL | 39.4851 mL | |
| 5 mM | 0.7897 mL | 3.9485 mL | 7.8970 mL | |
| 10 mM | 0.3949 mL | 1.9743 mL | 3.9485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
